- Home
- IMNM vs CET Comparison
IMNM vs CET Comparison
Compare IMNM & CET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IMNM | CET |
|---|---|---|
| Founded | 2006 | 1929 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.5B |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | IMNM | CET |
|---|---|---|
| Price | $19.42 | $50.29 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $26.89 | N/A |
| AVG Volume (30 Days) | ★ 1.2M | 51.4K |
| Earning Date | 11-06-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 4.59% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 7.40 |
| Revenue | $9,679,000.00 | ★ $27,062,484.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $6.79 |
| Revenue Growth | N/A | ★ 15.78 |
| 52 Week Low | $5.15 | $40.24 |
| 52 Week High | $20.46 | $52.44 |
Technical Indicators
Market Signals| Indicator | IMNM | CET |
|---|---|---|
| Relative Strength Index (RSI) | 60.95 | 53.96 |
| Support Level | $16.81 | $49.63 |
| Resistance Level | $20.46 | $50.79 |
| Average True Range (ATR) | 1.20 | 0.82 |
| MACD | 0.03 | 0.18 |
| Stochastic Oscillator | 72.74 | 88.15 |
Price Performance
Historical ComparisonAbout IMNM Immunome Inc.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.
About CET Central Securities Corporation
Central Securities Corp is a non-diversified closed-end management investment company. Its investment objective is long-term growth of capital. The company invests in common stocks, bonds, convertible bonds, preferred stocks, convertible preferred stocks, warrants, options real estate, or short-term obligations of governments, banks, and corporations.